Abliva (OMX: ABLI)

Currency in -

Last close As at 06/02/2023


−0.01 (−5.56%)

Market capitalisation


Edison Investment Research is terminating coverage on Abliva. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.


Previously published reports can still be accessed via our website.



Balance Sheet

Forecast net debt (SEKm)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.4) (11.9) (72.7)
Relative (0.9) (20.7) (63.8)
52 week high/low SEK0.6/SEK0.2


Abliva is a Swedish biotech company with deep expertise in mitochondrial medicine. Its focus area is primary mitochondrial diseases with lead assets KL1333, an NAD+ modulator (Phase II/III ready), and NV354, a succinate prodrug (preclinical). It plans to start a pivotal Phase II/III trial with KL1333 in selected primary mitochondrial disorders this year.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (fd) (öre) P/E (x) P/CF (x)
2020A 1.9 (55.0) (57.4) (23.00) N/A N/A
2021A 0.2 (117.9) (120.4) (34.44) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free